Chronic rhinosinusitis with nasal polyps

The PBS subsidises mepolizumab for patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with mepolizumab under the National Health Act 1953, section 100 for patients with CRSwNP.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing mepolizumab.

Section 100 arrangements

mepolizumab

This item is only PBS-subsidised for non-admitted patients, day admitted patients, or patients on discharge who are attending:

  • an approved private hospital
  • a public hospital.

This item isn’t PBS-subsidised for public hospital in-patients. You must include the hospital name and provider number on the authority application form.

Treatment specifics

To be eligible for PBS-subsidised treatment with mepolizumab, patients must be treated by one or more of the following:

  • respiratory physician
  • clinical immunologist
  • allergist
  • ear nose and throat specialist
  • general physician with expertise in managing CRSwNP.

Authority applications

Applying for initial treatment

Apply for initial authority approval to prescribe PBS-subsidised mepolizumab to treat CRSwNP in writing and either:

All written applications must include:

Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised mepolizumab to treat CRSwNP can be made either:

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 17 June 2024.
QC 64522